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Abstract
Metal-on-metal hip resurfacing arthroplasties (MoMHRAs) have a high failure rate due to pseudotumour formation. It is not
certain whether pseudotumours in bilateral MoMHRAs form on the basis of an adverse reaction to metal debris (ARMD)
that is entirely due to a local innate and adaptive immune response to Cobalt-Chrome (Co-Cr) wear particles. To determine if
there is a systemic component to ARMD in bilateral MoMHRAs, we examined the histology of ARMD in unilateral and
bilateral MoMHRAs revised for pseudotumour and determined whether implant survival differed between these two groups.
Periprosthetic tissue specimens from 119 hips revised for pseudotumour were examined. These were derived from 109
patients including 10 patients with bilateral MoMHRAs and 99 with sunilateral MoMHRAs including a cohort of 20 patients
with bilateral MoMHRAs that had undergone only one MoMHRA revision for pseudotumour. The mean time to revision for
pseudotumour of unilateral and bilateral MoMHRAs was determined. The histology of periprosthetic tissue was examined
for evidence of the innate and adaptive immune response and scored semi-quantitatively. There was no signiﬁcant difference
in histological features of the innate / adaptive response between Group 1 bilateral pseudotumours and Group 2 and Group 3
unilateral pseudotumours. Histological features, including ALVAL scores, were similar in the periprosthetic tissues of right
and left hips in Group 1 bilateral MoMHRAs. The mean time to ﬁrst revision for pseudotumour of bilateral MoMHRAs
(6.59 years) was not decreased compared with unilateral MoMHRAs (5.66 years) or bilateral MoMHRAs that had only one
revision (7.05 years). Right and left hip pseudotumours in bilateral MoMHRAs exhibit similar histological features of the
innate and adaptive immune response. Mean implant survival is not decreased in bilateral compared with unilateral
MoMHRA cases. The ﬁndings suggest that pseudotumour formation is due more to a local than a systemic innate /adaptive
immune response to components of metal wear.
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Graphical Abstract
1 Introduction
Metal-on-metal (MoM) hip resurfacing arthroplasties
(MoMHRAs) have been associated with an unacceptably
high early/mid-term failure rate due to an adverse reaction
to metal debris (ARMD) [1–3]. Hip MoM implants produce
large amounts of nanometre-sized cobalt-chrome (Co-Cr)
wear particles and induce both an innate and adaptive
immune response to components of metal wear [4]. The
innate response is characterised by an inﬁltrate of foreign
body macrophages that phagocytose Co-Cr wear particles;
these particles are cytotoxic and can lead to macrophage
apoptosis and tissue necrosis. The adaptive immune
response is characterized by a focally heavy lymphocyte
and plasma cell inﬁltrate with collections of lymphoid cells
around vessels, a feature which has been termed “aseptic
lymphocyte-dominated vasculitis-associated lesion”
(ALVAL) [5]. Both the innate and adaptive immune
response contribute to ARMD and pseudotumour forma-
tion, the most common cause of MoMHRA failure [6, 7].
Bilateral hip joint arthroplasty, carried out as a one-stage,
or more commonly as a two-stage procedure, is sometimes
undertaken for patients who suffer from bilateral arthritic
conditions. A number of studies have shown that in bilateral
metal on polyethylene (MoP) arthroplasties carried out for
osteoarthritis and other arthritic conditions, outcomes are
similar to unilateral MoP arthroplasties in terms of implant
survival and other complications [8–10]. Hip MoM
implants, including MoMHRAs, have also been used to
treat bilateral hip arthritis [11–14]. Increased metal ion
levels have been correlated in some studies with the
development of ARMD and serum metal ion levels are
higher in patients with bilateral compared with unilateral
MoMHRAs [14–17]. In a previous study, we reported
pathological ﬁndings in a small series of patients with
bilateral MoMHRAs that developed bilateral pseudotu-
mours [18]. Evidence of both an innate and adaptive
immune response was noted in the periprosthetic tissues of
both hip implants and it was hypothesized that a systemic
innate and adaptive response to components of metal wear
may have played a role in pseudotumour formation.
To determine if there is a systemic component to the
development of pseudotumours in bilateral MoMHRAs, we
have reviewed histological ﬁndings in a large number of
bilateral and unilateral MoMHRA cases revised for pseu-
dotumour. The degree of the innate and adaptive immune
response in these cases was assessed by determining the
extent of the foreign body macrophage and lymphocyte/
plasma cell (i.e., ALVAL) response respectively in peri-
prosthetic tissues. We correlated our results with implant
survival in order to examine not only whether there is a
systemic component to pseudotumour formation in bilateral
MoMHRAs but also whether there is a difference in out-
come between bilateral and unilateral MoMHRAs.
2 Materials and methods
2.1 Patient and implant data
One hundred and nineteen hips from 109 patients were
analysed. The cases were divided into three groups: -
Group 1 comprised 20 hips from 10 patients who had
revision of failed bilateral MoMHRAs for pseudotumour.
Patient and implant details from this cohort are shown in
Table 1.
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Group 2 comprised 79 hips from patients who had
revision of a failed unilateral MoMHRA for pseudotumour.
The implants were: Conserve (Conserve® Plus Total
Resurfacing Hip System, Wright Medical Technology,
Arington, TN, USA), in 37 cases; BHR (Birmingham
Hip Resurfacing System, Smith & Nephew, Memphis,
Tennessee, USA) in 32 cases; Recap (Recap® Femoral
Resurfacing system, Biomet, Warsaw, Indiana, USA) in 8
cases and Cormet (Cormet 2000TM, Corin, Lincester, UK)
in 2 cases.
Group 3 comprised 20 patients with bilateral MoMHRAs
who had undergone revision for unilateral MoMHRA fail-
ure due to pseudotumour. In these cases, no evidence
of a pseudotumour on the contralateral side was
identiﬁed on clinical assessment or cross-sectional imagin-
ing (see below). The implants were Conserve in 6
cases, BHR in 12 cases, Recap in 1 case and Cormet in 1
case.
Groups 2 and 3 were derived from a recent single-centre
prospective cohort study of 1429 MoMHRAs (1216
patients, 40% female) implanted between 1999 and 2009
[10], All cases had radiological evidence of a pseudotumour
on the basis of MRI, CT or ultrasound investigations. None
of the cases in Groups 1, 2 or 3 was revised for infection
and in all cases the index operation was carried out for
primary osteoarthritis.
2.2 Histopathological analysis
The specimens submitted included capsule/synovium,
femoral and acetabular membrane and pseudotumour. The
mean number of specimens submitted from each case was
six (range 2–13). None of the specimens had histological or
microbiological evidence of infection.
As a measure of the innate immune response, the extent
of the foreign body macrophage inﬁltrate in MoM peri-
prosthetic tissues was assessed in haematoxylin-eosin-
stained 5 μm tissue sections by histological analysis as
previously described [19]. The extent of macrophage inﬁl-
trate was as 1+ (few), 2+ (many), or 3+ (abundant) and
an assessment of necrosis also noted. The ALVAL response
was graded using the Oxford ALVAL scoring system
whereby: 0= no evidence of a perivascular lymphoid
inﬁltrate; 1= little evidence of perivascular lymphoid
inﬁltrate with lymphocyte cufﬁng of blood vessels being
fewer than 5 cells in thickness; 2= several perivascular
lymphoid aggregates with lymphocyte cufﬁng of vessels
being ﬁve to ten cells in thickness; 3= numerous large
perivascular lymphoid aggregates with lymphocyte cufﬁng
around vessels being more than ten cells in thickness [20].
As inﬂammatory changes are not uniform in periprosthetic
tissues, the ALVAL score was based on the maximum
perivascular lymphoid inﬁltrate noted in any one specimen.
Table 1 Bilateral MoMHRA patients, implant details and histological ﬁndings in pseudotumours
Case no. Sex Right/Left Age at op. Implant Head size Cup size Diagnosis Implant duration ALVAL grade Macrophage grade
1 F L 42.18 Conserve 46 52 Primary OA 6.64 1+ 3+
1 F R 43.77 Conserve 46 52 Primary OA 5.52 1+ 2+
2 F L 52.77 Recap 44 50 Primary OA 5.68 3+ 3+
2 F R 54.27 Recap 44 50 Primary OA 3.70 3+ 3+
3 F L 45.98 Conserve 40 46 Perthes 5.06 3+ 2+
3 F L 47.05 Conserve 42 48 Primary OA 6.41 3+ 3+
4 M L 52.48 BHR 50 56 Primary OA 8.31 3+ 3+
4 M R 52.48 BHR 50 56 Primary OA 12.05 3+ 3+
5 F R 48.00 BHR 50 56 Primary OA 5.44 3+ 2+
5 F L 48.36 BHR 50 56 Primary OA 7.61 3+ 3+
6 F R 49.45 BHR 46 52 Primary OA 9.11 3+ 3+
6 F L 50.16 BHR 46 52 Primary OA 8.40 3+ 2+
7 F R 64.68 BHR 50 56 Primary OA 2.12 3+ 2+
7 F L 64.90 BHR 50 56 Primary OA 0.79 3+ 2+
8 F R 54.79 BHR 46 52 Primary OA 10.45 3+ 3+
8 F L 54.95 BHR 46 52 Primary OA 11.54 3+ 3+
9 F R 49.62 BHR 50 56 Primary OA 8.94 3+ 2+
9 F L 57.08 BHR 54 56 Primary OA 1.80 3+ 3+
10 M L 57.60 BHR 46 52 Primary OA 6.45 2+ 3+
10 M R 59.01 Conserve 46 52 Primary OA 5.69 2+ 3+
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At least twenty ﬁelds per specimen (100× magniﬁcation)
were examined. The N-1 chi-square test was used to com-
pare histological ﬁndings between the two groups.
3 Results
3.1 Implant survival in bilateral and unilateral
MoMHRAs
The mean time to ﬁrst revision for the 20 pseudotumours in
the bilateral MoMHRA cases was 6.59 years (standard
deviation= 3.08 years; range 0.79–12.1 years; median=
6.43 years; IQR 3.70–9.11 years). The mean time to revi-
sion for pseudotumour in 79 unilateral MoMHRA revisions
for pseudotumour was 5.66 years (standard deviation 3.06
years; range 0.70–2.5 years; median= 5.65 years; IQR
1.10–10.1 years). In a further 20 bilateral MoMHRA cases
where only one of the MoMHRA had been revised for
pseudotumour, the mean time to revision of the MoMH-
RA’s for pseudotumour was 7.04 years (standard deviation
= 2.84 years; range 0.9–12.3 years; median= 7.05 years;
IQR= 3.70–10.9 years).
3.2 Histological ﬁndings
It was noted that similar histological features of ARMD
were present in periprosthetic tissues of pseudotumours in
both the right and left hips in (Group 1) bilateral MoMHRA
cases. Reﬂecting the innate immune response, a signiﬁcant
(2+/3+) macrophage response to wear particles was noted
in all cases; this was accompanied by extensive cell/tissue
necrosis, mainly on the surface of pseudotumours (Fig. 1).
A few scattered foreign body macrophage polykaryons
were noted in some specimens but these were not com-
monly seen in either bilateral (or unilateral) MoMHRAs.
Evidence of an adaptive immune response with a diffuse,
focally heavy lymphoid inﬁltrate that included lympho-
cytes, plasma cells and perivascular lymphoid aggregates
(i.e., ALVAL) was seen in all Group 1 pseudotumours with
80% of bilateral MoMHRA cases having a high (Grade 3)
Oxford ALVAL score in both right and left hips (Table 1;
Fig. 2). In one case the Oxford ALVAL score was Grade 1
in both hips and, in another case, the Oxford ALVAL score
was Grade 2 in both hips. Group 2 (unilateral MoMHRA
with one revised pseudotumour) and Group 3 (bilateral
MoMHRAs with one revised pseudotumour) also showed a
prominent macrophage inﬁltrate (2+/3+) and cell/tissue
necrosis in periprosthetic tissues. In Group 2 cases, the
Oxford ALVAL score was Grade 3 in 76% with 17.6 and
6.3% Grade 2 and Grade 1 respectively. In Group 3 cases,
the Oxford ALVAL score was Grade 3 in 70% with 20 and
10% Grade 2 and Grade 1 respectively. There was no
statistically signiﬁcant difference in ALVAL scores
between the two groups.
4 Discussion
National Joint Registry data indicate that MoM hip
implants, including MoMHRAs, have higher short/mid-
term failure rates compared with non-MoM articulations [2,
3]. Revision arthroplasty for MoMHRA failure is most
commonly carried out because of development of a pseu-
dotumour as a consequence of ARMD [7]. In this study, we
show that bilateral MoMHRAs revised for pseudotumour
exhibit similar pathological features of an innate and
adaptive immune response in both hips and that implant
survival in bilateral MoMHRAs is not decreased compared
with unilateral MoMHRAs which also exhibit features of
ARMD.
Fig. 1 Histological features of the innate immune response in a
pseudotumour showing: a surface tissue necrosis with underlying
inﬁltrate of macrophages conataining metal wear particles b macro-
phages containing granular metal wear particles including some black
particulate aggregates (some arrowed)
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The pathology of ARMD occurs as a consequence of the
innate and adaptive immune response to components of
metal wear [4]. The innate immune response is effectively a
non-speciﬁc foreign body macrophage response to the very
large number of nanometer-size Co-Cr particles generated
from MoM implants. These particles are coated with host
proteins derived from blood and interstitial ﬂuid and, fol-
lowing phagocytosis of the metal protein complex, trans-
ported to intracellular lysosomes where they undergo
corrosion, resulting in the release of Co and Cr ions. The
cytotoxic effect of metal ions on macrophages, ﬁbroblasts
and other cells in periprosthetic tissues is well recognised
and results in the marked tissue necrosis seen in ARMD
[21–23]. In patients with bilateral MoMHRAs, it is known
that there are high levels of metal ions in the circulation
[14–16]. Co and Cr ions have been detected in extra-
articular tissues remote from the implant site where they
have been shown to cause tissue damage [24]. Whether
elevated serum metal ion levels correlate with an increase in
implant failure due to ARMD is controversial [20, 25–27].
In vitro studies have shown that high levels of Co sig-
niﬁcantly decrease the viability of macrophages that have
phagocytosed metal wear particles [28, 29]. Increased
numbers of pseudotumours have been noted in patients with
bilateral compared unilateral MoM total hip replacements,
with higher blood metal ion levels being seen in bilateral
pseudotumour cases [30]. Although the results of these
investigations suggest that high blood metal ion levels in
patients with bilateral MoMHRAs may have an effect on
the innate immune response that leads to pseudotumour
formation, we noted a signiﬁcant (2+/3+) macrophage
inﬁltrate and necrosis in periprosthetic tissues in both
bilateral and unilateral MoMHRA cases, suggesting no
major additive effect in this regard.
The pathology of ARMD in periprosthetic tissues is also
often marked by a pronounced, perivascular lymphocyte
and plasma cell reaction termed ALVAL [4, 5]. This lym-
phoid response is thought to develop as a result of an
adaptive cell-mediated Type IV reaction to Co-Cr wear
particles, or, more speciﬁcally, cell and tissue components
altered by interaction with Co-Cr wear particles [4, 23]. Co-
Cr particles produce high levels of metal ions that act as
haptens which combine with large carrier (cell-or tissue-
derived) protein molecules that may become immunogenic,
resulting in a cell-mediated hypersensitivity response. When
pseudotumours associated with bilateral MoMHRAs were
ﬁrst reported, concerns were raised that the ARMD
response in the second MoMHRA may have resulted from
prior sensitization to metal wear from the ﬁrst MoMHRA in
a manner analogous to the Type IV metal hypersensitivity
reaction seen in contact dermatitis [18]. We noted that the
Oxford ALVAL score in peri-implant tissues of both right
and left MoM hips was similar in bilateral MoMHRAs. In
one case, a low Oxford ALVAL score (Grade 1) was seen in
both MoMHRAs peri-implant tissues, suggesting that there
was no additive effect from prior sensitization to metal
wear; similarly, in another case, the ALVAL score was
Grade 2 in both hips. In all other cases, the Oxford ALVAL
score was high (Grade 3), indicating that there was a pro-
nounced adaptive immune response to metal wear particles
in both hips. Madanat et al in an MRI study also noted
symmetry of adverse local tissue reactions in patients with
bilateral simultaneous and sequential MoMHRAs [31]. As
noted previously [27], we found that most unilateral
MoMHRA cases have a high (Grade 3) Oxford ALVAL
score. Unilateral MoMHRAs and bilateral MoMHRA cases
with revision of only one MoMHRA also showed no sig-
niﬁcant difference in the ALVAL response histologically.
It has been stated that patients with bilateral MoMHRAs
have a higher risk of developing ARMD [32]. Our results
show, however, that implant survival in unilateral and
bilateral MoMHRAs revised for pseudotumours is not
markedly different. In fact, implant survival was slightly
Fig. 2 Right hip pseudotumour (Case 4) showing: a two (Oxford
Grade 2/3) ALVAL collections in capsular fat and ﬁbrous tissue. b
High-power view showing numerous lymphocytes in one of the
ALVAL collections
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higher in bilateral compared with unilateral MoMHRAs,
including cases that had bilateral MoMHRAs where only
one implant had been revised for pseudotumour. Implant
survival has not been shown to be signiﬁcantly different in
bilateral hip replacements using other forms of articulation
such as MoP [8–10]. The absence of a difference in implant
survival between unilateral and bilateral MoMHRAs, cou-
pled with our histological ﬁndings that there is no sig-
niﬁcant difference in the innate and adaptive immune
response between unilateral and bilateral MoMHRAs,
suggests that higher metal ion levels and prior sensitization
to metal wear components in bilateral MoMHRAs does not
appear to signiﬁcantly inﬂuence pseudotumour formation.
Our study has several limitations, including the absence of
measurement of Co and Cr levels in the cases studied and
the use of archival data in a retrospective study involving
different implant types. In addition, our histological ﬁndings
were restricted to identifying the main cell types involved in
the innate and adaptive immune response to components of
metal wear in periprosthetic tissues ie foreign body mac-
rophages and lymphocytes/plasma cells respectively [4–6];
we did not assess the role of other inﬂammatory cells (eg
dendritic cells, natural killer cells, eosinophils) and humoral
factors (e.g., interleukins, tumour necrosis factor, inter-
feron-gamma) that are known to play a role in innate and
adaptive immunity [33–35]. However, our ﬁndings would
indicate that ARMD and pseudotumour formation occur
principally as a result of a local rather than systemic reac-
tion to components of metal wear.
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